![]() |
市場調查報告書
商品編碼
1792427
2025 年至 2033 年尼古丁口香糖市場報告(按類型、應用、配銷通路和地區)Nicotine Gum Market Report by Type, Application, Distribution Channel, and Region 2025-2033 |
2024年,全球尼古丁口香糖市場規模達17億美元。展望未來, IMARC Group預計到2033年,該市場規模將達到25億美元,2025-2033年期間的複合年成長率(CAGR)為4%。推動全球市場成長的因素有很多,包括戒菸計劃、健康意識的增強,以及對便捷的非處方(OTC)尼古丁替代療法的需求不斷成長。提升產品功效的技術創新也為市場帶來了顯著的價值。
戒菸計劃和健康意識
全球範圍內的吸煙減少措施以及健康意識的不斷增強,正在推動市場擴張。隨著人們對吸菸相關健康風險的認知不斷提高,人們正在積極尋找有效的戒菸策略。尼古丁口香糖是一種戒菸輔助工具,它透過逐漸且可控地釋放尼古丁來幫助使用者控制戒斷症狀。此外,由醫療機構和監管機構推出的各種戒菸計畫也為尼古丁口香糖的需求創造了良好的環境。由於大眾對健康的重視以及持續的禁煙努力,這種口香糖作為戒菸治療的重要組成部分越來越受到人們的認可,這推動了市場的成長。 2023年4月11日,衛生部長尼爾·奧布萊恩在政策交流會上發表演講,介紹了政府降低吸菸率和打擊未成年人吸電子煙的計畫。
非處方尼古丁替代療法的需求不斷成長
根據IMARC Group的數據,2023 年全球非處方藥產業規模為 1,687 億美元。推動市場發展的主要因素之一是對非處方尼古丁替代藥物的需求不斷成長。這種口香糖是一種易於取得的非處方解決方案,使用者無需處方即可自行治療。對於想要戒菸而又不想尋求醫療協助的人來說,這種口香糖之所以受歡迎,是因為它易於取得且使用方便。人們在管理健康方面變得更加積極主動,這為尼古丁口香糖市場前景提供了積極的推動力。此外,2024 年 1 月 24 日,戒菸工作取得了重大突破,在奧裡薩邦克塔克的 Sri Ram Chandra Bhanja (SCB) 牙科學院和醫院進行的一項臨床試驗表明,尼古丁替代療法 (NRT) 與行為療法相結合具有顯著的療效。
技術進步與產品創新
尼古丁替代療法配方和管理方面的持續技術改進和產品創新正在推動市場成長。尼古丁口香糖公司正在投入大量資金進行研發 (R&D) 活動,以提高產品的效能和使用者體驗。使用者之所以接受這些口香糖,是因為其具有增強的口味和獨特的輸送系統等創新功能。此外,對尼古丁成癮和戒斷過程的深入了解也有助於開發更有效的口香糖配方。對更有效的戒菸解決方案日益成長的需求正在推動尼古丁口香糖市場的成長。除此之外,市場上的公司正在獲得公認機構的產品批准。例如,Perrigo Company plc (PRGO) 於 2023 年 5 月 16 日獲得了美國食品藥物管理局 (FDA) 的最終批准,可生產 2 毫克和 4 毫克的尼古丁包衣薄荷味 OTC 含片。該產品有助於減輕試圖戒菸的消費者的戒斷症狀。此外,它將以零售商商店品牌標籤進行銷售,作為與 Nicorette 塗層冰薄荷糖類似的產品。
對於那些希望在戒菸過程中減少尼古丁攝取的人來說,2毫克尼古丁口香糖是個合適的選擇。 2毫克尼古丁口香糖是控制戒斷症狀並逐步擺脫尼古丁依賴的理想替代品,是輕度至中度吸菸者的理想選擇。此外,它還建議需要逐步戒斷策略和戒菸初期的人士使用,以便更規律地過渡到無尼古丁的生活。
醫療實踐佔據行業最大佔有率
尼古丁口香糖在醫療環境中用於更全面的戒菸計劃。醫生可能會將這種口香糖推薦給患者,作為個人化戒菸方案的一部分,或在常規諮詢中服用。口香糖中尼古丁的漸進式和調節性釋放與實證療法相符。在醫療實踐應用中,強調了醫療保健專業人員在幫助人們戒菸方面的重要性,以及使用尼古丁口香糖帶來的健康益處和個人化幫助。
零售藥局是主要的細分市場
尼古丁口香糖在零售藥局很容易買到。尋找戒菸產品的消費者可以輕鬆地在家附近找到它們。這種口香糖很容易買到,藥劑師也可以提供相關的用藥建議,這使得它成為那些尋求面對面支持和快速獲得戒菸產品的人的首選。
北美領先市場,佔據尼古丁口香糖最大市場佔有率
該報告還對所有主要區域市場進行了全面分析,包括北美(美國和加拿大);亞太地區(中國、日本、印度、韓國、澳洲、印尼等);歐洲(德國、法國、英國、義大利、西班牙、俄羅斯等);拉丁美洲(巴西、墨西哥等);以及中東和非洲。報告指出,北美是尼古丁口香糖最大的區域市場。
北美憑藉其強大的戒菸力度、日益增強的健康意識以及龐大的消費者群體,成為重要的市場。該地區擁有完善的醫療基礎設施和積極的監管措施,這些因素促使尼古丁口香糖成為首選的戒菸輔助工具。此外,在北美地區,尋求有效戒菸解決方案的人數也不斷增加。此外,尼古丁口香糖在零售藥局和線上商店等各種分銷管道的廣泛供應也有助於增加尼古丁口香糖市場的收入。 2024年3月18日,全球領先的合約開發和製造組織 (CDMO) Cambrex 宣布完成一項為期5年、總額達1億美元的投資策略,比原計劃提前一年完成。該項目將為其北美和歐洲 70% 的藥物開發和製造網路增加超過 150,000 平方英尺的產能和能力擴展,並將於 2024 年底完成。投資涵蓋所有規模的臨床和商業藥物物質製造,並包括解決與複雜分子相關的挑戰的先進技術。
The global nicotine gum market size reached USD 1.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4% during 2025-2033. There are various factors that are responsible for the growth of the global market, which include smoking cessation initiatives and heightened health awareness, rising demand for convenient over the counter (OTC) nicotine replacement therapies. Technological innovations for enhancing product efficacy also add significant value to the market.
Smoking Cessation Initiatives and Health Awareness
Global efforts to reduce smoking, along with rising health awareness, are propelling the market expansion. People are actively looking for effective strategies to quit smoking as awareness about health risks connected with smoking increases among them. Nicotine gum is a smoking cessation aid that helps users manage the symptoms of withdrawal by releasing nicotine gradually and under control. In addition, various smoking cessation programs by healthcare organizations and regulatory authorities has created a favorable atmosphere for nicotine gum demand. The rising acceptance of this gum as an essential component of smoking cessation treatments due to the emphasis on public health and the ongoing efforts to eliminate smoking is impelling the market growth. On 11 April 2023, Neil O'Brien, Health Minister, delivered a speech at Policy Exchange on government plans to cut smoking rates and tackle underage vaping,
Growing Demand for OTC Nicotine Replacement Therapies
As per the IMARC Group, in 2023, the size of the OTC medication industry worldwide was US$ 168.7 Billion. One of the main factors propelling the market is the rising demand for OTC nicotine replacement medicines. This gum is an easily available OTC solution that enables users to self-administer therapy without a prescription. This gum's popularity as a top option for people trying to stop smoking without seeking medical help is due to its accessibility and ease of usage. People are becoming more proactive in managing their health, which is offering a positive nicotine gum market outlook. Furthermore, on 24 January 2024, in a significant breakthrough for tobacco cessation efforts, a clinical trial conducted at Sri Ram Chandra Bhanja (SCB) Dental College and Hospital in Cuttack, Odisha, unveiled the remarkable efficacy of nicotine replacement therapy (NRT) when combined with behavioral therapy.
Technological Advancements and Product Innovation
Continuous technological improvements and product innovations in the formulation and administration of nicotine replacement therapies are bolstering the market growth. Nicotine gum companies are spending money on research and development (R&D) activities to enhance the effectiveness of product as well as user experience. Users are adopting these gums owing to innovations like enhanced flavors and unique delivery systems. In addition, enhanced understanding of nicotine addiction and withdrawal processes are benefiting in the creation of gum formulations that are more efficient. The escalating demand for more efficient smoking cessation solutions is bolstering the nicotine gum market growth. Besides this, companies in the market are getting product approvals from the recognized authorities. For instance, Perrigo Company plc (PRGO) received final approval from the Food Drug Administration (FDA) for nicotine coated mint lozenges 2 mg and 4 mg OTC on 16 May 2023. The product helps in reducing withdrawal symptoms in consumers who are trying to quit smoking. Moreover, it will be marketed under retailer's store brand labels as a comparable offering to Nicorette coated ice mint lozenge.
Those looking to cut back on their nicotine intake during their journey to quit smoking can find 2 mg category a suitable choice. 2mg nicotine gum is an ideal alternative for controlling withdrawal symptoms while progressively weaning off nicotine dependence, making it the perfect choice among light to moderate smokers. Furthermore, it is advised for people who need a step-down strategy and in the early phases of quitting in order to enable a more regulated shift to a life free of nicotine.
Medical practice holds the largest share of the industry
Nicotine gums are used in more comprehensive smoking cessation programs in medical settings. Physicians may recommend this gum to patients as part of individualized smoking cessation regimens or during routine consultations. The progressive and regulated release of nicotine from the gum is consistent with evidence-based therapies. In the medical practice application, the importance of healthcare professionals in helping people quit is emphasized, along with the health advantages and individualized assistance that come with using nicotine gum.
Retail pharmacies represent the leading market segment
Nicotine gums are readily available at retail pharmacies. Consumers in search of smoking cessation products can easily locate them in close proximity to their homes. This gum is easily available and pharmacists can offer their advice related to medication, which makes it a favored option for those seeking person-to-person support and quick access to quit smoking products.
North America leads the market, accounting for the largest nicotine gum market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for nicotine gum.
North America stands as a significant market due to robust smoking cessation efforts, heightened health awareness, and a substantial consumer base. The region has a well-established healthcare infrastructure and proactive regulatory measures that contribute to the popularity of these gums as a preferred smoking cessation aid. In addition, there is an increase in the number of individuals seeking effective solutions to quit smoking in the North America region. Besides this, the wide availability of these gum across various distribution channels including retail pharmacies and online stores, assists in increasing nicotine gum market revenue. On 18 March 2024, Cambrex, a leading global contract development and manufacturing organization (CDMO), announced the completion of a 5-year, US$ 100-Million-dollar investment strategy, one year ahead of schedule. The project adds more than 150,000 square-feet of capacity and capability expansions across 70% of its North American and European drug development and manufacturing network, which will be completed by the end of 2024. The investments span all scales of clinical and commercial drug substance manufacturing and include advanced technologies to solve for challenges related to complex molecules.